

Late 1990s
Early development begins in China and Vietnam

2001
Guangzhou University commences Chinese development of DHA-PQP

2003
Sigma-Tau and Italian MoH discuss how to strengthen Italy's contribution to malaria

2005-2007
Clinical development programme in Asia and Africa

2007-2009
API transfer from China to India

2010-2011
Additional clinical and nonclinical studies completed

2001
DHA PQP identified as top priority for at Shanghai meeting

2004
Agreement signed between MMV, Sigma-Tau, Oxford University and Holleykin

2007
Orphan designation granted by the European Commission

2009
Sigma-Tau submits dossier to EMA for marketing authorisation

2011
European Commission grants marketing authorisation

2012
160,000+ packages of Eurartesim delivered to Cambodia to fight drug resistance